Literature DB >> 9660021

Dual blockade of P-selectin and beta2-integrin in the liver inflammatory response after uncontrolled hemorrhagic shock.

R Anaya-Prado1, L H Toledo-Pereyra, J T Collins, R Smejkal, J McClaren, L D Crouch, P A Ward.   

Abstract

BACKGROUND: Neutrophil infiltration is a characteristic feature of the hepatic injury associated with prolonged hypotension. Previous work has already stressed the important contribution of neutrophil-endothelial cell interactions in the organ injury seen after hemorrhagic shock. Single-blockade strategies using monoclonal antibodies (MAbs) against either selectin or integrin receptors have been demonstrated to be effective in limiting the tissue inflammatory response observed in this clinical disorder. One unexplored topic is the additive effect(s) and the potential antiinflammatory properties of the combined blocking of P-selectin plus beta2-integrin in the liver inflammatory response after uncontrolled hemorrhagic shock in rats. STUDY
DESIGN: Sprague-Dawley rats (n = 64) weighing 250-300 g were included in a three-phase model of uncontrolled hemorrhagic shock. A prehospital phase consisted of 90 minutes of fluid resuscitation with lactated Ringer's solution to reach a mean arterial pressure (MAP) of 40 mmHg; a hospital phase consisted of 60 minutes of hemostasis and fluid resuscitation with lactated Ringer's solution to reach a MAP of 80 mmHg; and the third phase was 3 days of observation. All rats had 3 mL/100 g of blood volume shed during the initial 15 minutes. At 30 minutes, 75% tail amputation produced uncontrolled hemorrhagic shock. Four groups were randomized (n = 16 per group), and treatment at the beginning of resuscitation included normal saline (group 1); anti-P-selectin MAb, RMP-1 (group 2); anti-beta2-integrin MAb, WT.3 (group 3); or anti-P-selectin plus anti-beta2-integrin MAbs (group 4). The following indices were evaluated: fluid requirements for resuscitation, liver injury tests, liver tissue myeloperoxidase, and liver histology.
RESULTS: Dual blockade of P-selectin and beta2-integrin significantly reduced fluid requirements for resuscitation (p < 0.05). We also observed a statistically significant improvement (p < 0.05) in tests demonstrating hepatic injury, myeloperoxidase in hepatic tissue, and histology studies. Survival was increased from 40% in controls to 60% with the dual-blockade treatment.
CONCLUSIONS: These results indicate that dual-blockade strategies aimed at P-selectin and beta-integrin provided a protective effect in the liver inflammatory response after uncontrolled hemorrhagic shock in rats. Although dual blockade was more effective than either individual blockade alone, questions remain about the possible redundancy in the inflammatory adhesion pathways after this clinical condition.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9660021     DOI: 10.1016/s1072-7515(98)00125-2

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  4 in total

1.  A new model of severe hemorrhagic shock in rats.

Authors:  Thomas Rönn; Sven Lendemans; Herbert de Groot; Frank Petrat
Journal:  Comp Med       Date:  2011-10       Impact factor: 0.982

2.  Indices of muscle and liver dysfunction after surviving hemorrhage and prolonged hypotension.

Authors:  Carmen Hinojosa-Laborde; Robert E Shade; Patrice A Frost; John W Dutton; Gary W Muniz; Ian L Hudson; Robert Carter; Kathy L Ryan
Journal:  J Trauma Acute Care Surg       Date:  2019-07       Impact factor: 3.313

3.  Integrin-mediated laminin-1 adhesion upregulates CXCR4 and IL-8 expression in pancreatic cancer cells.

Authors:  John J Grzesiak; Kathy C Smith; Douglas W Burton; Leonard J Deftos; Michael Bouvet
Journal:  Surgery       Date:  2007-05-04       Impact factor: 3.982

4.  Latent effects of fibronectin, alpha5beta1 integrin, alphaVbeta5 integrin and the cytoskeleton regulate pancreatic carcinoma cell IL-8 secretion.

Authors:  A G Lowrie; D M Salter; J A Ross
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.